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Breast cancer represents the leading cause of death in women worldwide.  Ionizing radiation is one of the most 
relevant therapeutic approaches for the treatment of this type of cancer. Unfortunately, either resistance of 
tumor cells to therapeutic doses of radiation or normal tissue tolerance have proven to limit the effectiveness of 
radiotherapy. In the last few years, several studies have highlighted an important link between radioresistance, 
cancer and microRNAs (miRNAs), an emerging class of endogenous non coding RNAs that control gene 
expression. MiRNAs influence carcinogenesis at multiple stages and effectively control tumor radiosensitivity as 
they affect levels of target genes regulating relavant radio-related signal transduction pathways. Since radiation- 
and multidrug-resistances are the characteristic properties of numerous type of tumors, there is a huge interest 
in understanding the connection between miRNA expression in tumors and chemo- or radio-sensitivity. In the 
present review, we summarize the emerging evidence of miRNAs involvement in the radioresponse of breast 
tumors and discuss their potential role of radiosensitizers. 
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Introduction 
Breast Cancer (BC) constitutes a heterogeneous tumor 
type entity characterized by a complex spectrum of 
malignant features and clinical outcomes. The optimal 
management of BC requires a multidisciplinary approach and 
Radiation Therapy (RT) still represents one of the most 
effective treatment modalities. Unfortunately, efficacy of 
radiation treatment is limited by intrinsic radioresistance of 
cancer cells, which correlates with an increase in the risk of 
tumor local recurrence [1].  
How to reduce tumor radioresistance and improve 
radiosensitivity is indeed a hot topic in the field of RT, which 
explains the high interest in identifying new molecules 
endowed with synergistic effects with radiation.  
Recently, the discovery of microRNAs (miRNAs), a class 
of functional, non-coding small RNAs has changed the 
landscape of cancer biology [2]. MiRNAs (generally 21 to 24 
nucleotides in length) are a large family of non-coding RNAs 
acting as post-transcriptional regulators of gene expression. 
MiRNA genes are transcribed by RNA polymerase II as 
large primary transcripts (pri-miRNA) that are processed by 
a protein complex containing the RNase III enzyme Drosha, 
to form an approximately 70 nucleotide precursor microRNA 
(pre-miRNA). Such precursor is then transported to the 
cytoplasm where it is processed by the RNase III enzyme 
DICER, to form a mature miRNA of approximately 22 
nucleotides. The mature miRNA is then incorporated into a 
ribonuclear particle to form the RNA-induced silencing 
complex (RISC), which binds the 3’ untranslated region (3’ 
UTR) of the mRNA and mediates gene silencing. For more 
detailed mechanistic knowledge on miRNA mechanism of 
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action, we indeed recommend to the readers other specialized 
reviews [2, 3, 4].  
The most deleterious damage induced by ionizing 
radiation (IR) is thought to be the double strand breaks 
(DSBs) of DNA, resulting from the generation of excision 
repair breaks opposite each other on the two DNA strands, 
and by the formation of an excision repair break opposite a 
DNA daughter-strand gap [5]. If unrepaired, DSBs may affect 
cell survival, as they lead to chromosome aberrations, 
genomic instability and even cell death [6]. Human cells 
respond to DNA damage by activating the DNA damage 
response (DDR), a molecular machinery which detects and 
repairs DNA damage. DSBs are processed either by 
non-homologous end joining (NHEJ) or homologous 
recombination (HR): while NHEJ promotes the potentially 
inaccurate ligation of DSBs, HR precisely restores the 
genomic sequence of the broken DNA ends by exploiting 
sister chromatids as template for repair. DNA repair is 
carried out by a plethora of enzymatic activities aimed at 
repairing the DNA damage, which include several enzymes 
such as nucleases, helicases, polymerases, recombinases, 
ligases and many others [7,8]. 
MiRNAs regulate almost every cellular pathway, 
including the DDR [9]. A high interest in the applications of 
miRNAs in radiation oncology is due to their deep 
involvement in the DDR process [10]. 
How specific miRNAs regulate cancer radioresistance and 
can be used as radiosensitizing agents is now a matter of 
investigation. Therefore, understanding the correlation 
between miRNAs and RT will provide possible 
improvements in the current standard therapy of BC.  
MiRNAs influence RT by affecting specific cellular 
pathways 
The cellular exposure to IR triggers various physiological 
responses including DNA damage processing, cell cycle 
arrest, differentiation, signal transduction alterations, 
mutations, gene expression modifications, genomic 
instability and induction of carcinogenesis. Increased 
evidence supports a role for miRNAs in regulating key 
cellular pathways involved in response to radiation [11]. 
Recent studies have demonstrated that miRNAs influence 
many stages of carcinogenesis and can effectively modulate 
tumor radiosensitivity at different levels, by affecting targets 
involved in DNA damage repair, cell cycle checkpoint, 
apoptosis, signal transduction pathways and tumor 
microenvironment [12, 13].  
The most common injury produced by IR is DSB, then 
cancer cells activate several signaling pathways to repair 
DNA damage. Noteworthy, tumor cells may utilize both the 
two major pathway, i.e. the NHEJ or the HR, to repair DNA 
breaks. 
 MiRNAs are involved in regulating at the 
post-transcriptional level the expression of important targets 
in the DDR pathway [14, 15]. Indeed, miRNAs have been 
shown to efficiently modulate tumor radiosensitivity by 
blocking both the NHEJ and HR repair pathways involved in 
the DDR; they have proven to interfere with the major 
pathways activated by ionizing radiation, such as the 
PI3-K/Akt, NF-κB, MAPK and TGFβ signaling pathways 
[16]. 
Herein, many examples of well-characterized miRNAs 
involved in these processes are discussed.  
Lal et al. showed that miRNAs down-regulate DSB repair 
factors and suppress DNA repair in terminally differentiated 
blood cells [17]. BRCA1 plays essential roles in HR, NHEJ 
and nucleotide excision repair, by interacting with 
components of the DNA repair machinery and regulating 
expression of genes involved in DDR pathways [18]. 
However, BCRA1 deficiency also determines sensitivity to 
DNA-damaging agents such as PARP inhibitors. The 
over-expression of miR-182, through the use of miRNA 
mimics or by a lentiviral vector, induced a down-regulation 
of BCRA1 with the consequent enhancement of in vitro 
radiosensitivity of BC cells. On the basis of these findings, 
the authors postulated that miR-182-dependent targeting of 
BRCA1 hampers DNA repair in BC cells [19].  
The chromatin remodeling complex SNF2H (also known 
as SMARCA5) has been shown to regulate both the HR and 
NHEJ DNA repair pathways. In a study by Mueller et al., it 
has been shown that the down-regulation of miR-99 family 
members might represent a mechanism by which cancer cells 
acquire resistance to DNA damage by increasing DNA repair 
efficiency and consequently making cancer cells more 
resistant to RT. IR-induced miR-99 up-regulation reduced 
the capability of cells to repair DNA damage by regulating 
the expression of SNF2H and increasing radiosensitivity of 
MCF7 BC cells [20].  
RAD51 and RAD52 represent other two essential proteins 
implicated in DSBs repair and HR. RAD51 plays the critical 
role of catalyzing the transfer of the strand, between a broken 
sequence and its undamaged homolog, to resynthetize the 
damaged DNA region. MiR-155 was shown to target the 3′- 
UTR of RAD51, and miR-155 over-expression in vitro and 
in vivo regulated DNA repair activity and sensitivity to IR by 
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repressing RAD51 in BC, inducing a delay in repair after IR 
exposure [21]. Another miRNA, miR-302a, inversely 
correlated with AKT1 and RAD52 expression levels; 
inhibition of miR-302 conferred radioresistance while 
miR-302 over-expression sensitized BC cells to RT [22].  
The Ser/Thr kinase ataxia telangiectasia mutated (ATM) is 
the principal signaling molecule in response to DSBs. The 
activation of ATM occurs within minutes of a DSB, 
independently of the cell cycle’s phase [23]. ATM is the main 
player in DDR initiating the cascade leading to cell cycle 
checkpoint activation and DNA repair [24]. Importantly, ATM 
is directly regulated by several miRNAs [25,26], whose 
over-expression was found to reduce ATM expression and to 
radio-sensitize different tumor cell lines, including BC cell 
lines. 
Song et al. showed that ATM protein kinase was targeted 
by miR-18a; furthermore, they demonstrated that 
over-expression of miR-18a down-regulated ATM 
expression by targeting the ATM-3’-UTR, thus resulting in a 
reduction of both DDR and HRR efficiencies, and in an 
increase in cellular radiosensitivity to IR treatment [27]. A 
recent study by Zhang et al. has indicated that miR-205 
promoted radiosensitivity and that it was down-regulated in 
radioresistant subpopulations of BC cells; loss of miR-205 
highly associated with poor distant relapse-free survival in 
BC patients. MiR-205 inhibited DDR and radiosensitized 
tumor cells by targeting ZEB1 and Ubc13; in turn, radiation 
suppressed miR-205 expression through ATM and zinc 
finger E-box binding homeobox 1 (ZEB1), a crucial 
epithelial to mesenchymal transition (EMT) activator by 
inhibiting E-cadherin expression [28, 29]. EMT is essential in 
cancer invasion, metastatic dissemination and drug-resistance 
[30]. Moreover, miR-205 targeted the human epidermal 
growth factor receptor 3 (HER3), a receptor tyrosine kinase 
of the epidermal growth factor receptor (EGFR) family, 
thereby inactivating the downstream signals mediated by 
Akt, suppressing the phosphoinositide 3-kinase (PI3K)/Akt 
pathway and inhibiting BC proliferation with better 
responses to targeted therapies [31, 32].  
The role of miR-200c in the EMT process has been 
extensively studied. Up-regulation of miR-200c inhibited 
cancer aggressiveness, metastases and chemoresistance in 
some tumors [33, 34]. Lin et al. found out that BC cells bearing 
high expression of miR-200c displayed higher 
radiosensitivity. MiR-200 was also shown to directly target 
TANK-binding kinase (TBK1), which directly activates 
AKT [35]. Given the well known association between the 
PI3-K/AKT pathway and the radiation resistance 
mechanisms [36], a direct inhibition of such pathway led to an 
increased radiosensitivity of cancer cells.  
Specific histone modifications are essential steps of DDR 
[9]. To allow DNA repair, the repair proteins have to be 
recruited and to gain access to the site of DNA damage, 
which is normally packed inside a nucleosome. The histone 
variant H2AX is phosphorylated by ATM (γH2AX) in 
response to DSB and is part of the cascade that leads to DNA 
repair [37]. Presumably, γ-H2AX foci attract repair factors, 
leading to their accumulation at DSB site. Specific 
recognition of γ-H2AX by these repair factors requires the 
presence of protein domains, which bind to the 
phosphorylated carboxy-terminus of γ-H2AX. MiR-138 
targets H2AX [38]; over-expression of miR-138 led to higher 
chromosomal breaks and sensitivity to IR and cytotoxic 
drugs in the BC cell line MDA-MB231. H2AX with miR 
let-7 and caspases are also targets of Lin28, a marker of 
cancer stem cells, which is implicated in the mechanism of 
radioresistance of lung, pancreatic and BC cells. Wang et al. 
provided evidence that Lin28 expression was up-regulated in 
radiation-resistant BC cells and that Lin28 transfection 
induced radiation resistance; furthermore, the authors 
showed that over-expression of Lin28 and radiation 
effectively induced H2AX expression and inhibited γ-H2AX 
and p21 expression, while let-7 overexpression enhanced 
sensitivity to radiation [39].   
Cell cycle checkpoints are generally activated by DNA 
damage. One of the key proteins in the checkpoint pathways 
is represented by the tumor suppressor gene p53 [40], which 
coordinates DNA repair with cell cycle progression and 
apoptosis. P53 mediates the two major DNA 
damage-dependent cellular checkpoints, one at the G1/S 
transition and the other at the G2/M transition. G2/M, 
together with the latter part of the S phase, is the most 
radiosensitive phase of the cell cycle. For this reason, RT 
may be more effective with a partial synchronization in such 
radiosensitive phases of the cell cycle [41]. Anastasov et al. 
studied the regulation of cellular response to RT by 
miR-21-mediated modulation of cell cycle progression in BC 
cells. MiR-21 is considered a promising target in radiation 
therapy [42], especially for the possible functional link 
between miR-21 and the p53 tumour suppressor pathway, 
where p53-induced proteins evoke apoptosis in response to 
DNA damage after irradiation. In this study, miR-21 was 
reported to promote radioresistance of BC cells by inducing 
G2/M cell cycle arrest; anti-apoptotic effects triggered by 
miR-21 expression  was also evident after IR exposure and 
correlated with radioresistance. In addition, miR-21 
influenced cell cycle progression via DNA damage-G2 
checkpoint induction; in this way, miR-21 inhibition by 
antagomiRs was able to reduce the G2/M block and to 
potentiate apoptotic cell death induction after RT [43].  
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One of the direct targets of p53 is miR-34, and it has been 
shown that miR-34 plays a role in cell cycle arrest, inhibition 
of proliferation and apoptosis. After radiation injury, several 
miRNA profiling strategies detected miR-34 family members 
as upregulated in different types of human cell lines [9, 44], as 
well as in the nematode Caenorhabditis elegans model 
system [45].  
miRNAs as predictive biomarkers in BC-RT 
Since RT remains one of the most important methods for 
the treatment of BC, there is a great interest in identifying 
factors which might help to predict patients’ response to 
treatment. Importantly, predicting the response to RT, by 
distinguishing between radioresistant and radiosensitive 
patients, could be helpful to minimize the risk of unnecessary 
treatment and the consequently related side effects. Recent 
studies have demonstrated the potential role of miRNAs as 
predicting biomarkers of patient response to different 
treatments including chemotherapy and RT [46, 47]. The 
potential of miRNAs to correlate with response to a given 
treatment, and their remarkable stability in blood and serum, 
make miRNAs novel potential diagnostic and prognostic 
biomarkers in the personalized management of BC [48].  
Accumulating evidence is underlying the possible 
contribution of miRNAs as valuable biomarkers to predict 
response to chemotherapy [49]. For instance, down-regulation 
of miR-34, miR-17 and miR-7a associated with 
chemosensitivity to fluorouracil, adriamycin and 
cyclophosphamide, respectively [50]. In preclinical studies 
employing BC cell lines, miR-21 inhibition correlated with 
increased sensitivity to topotecan and taxol [51]. Moreover, 
circulating miR-210 and miR-125b were associated with 
sensitivity to trastuzumab and resistance to neo-adjuvant 
chemotherapy, respectively [52, 53]. 
On the other hand, few clinical studies have demonstrated 
the impact of miRNAs to RT response. In a recent study by 
Halimi et al., the hypothesis of a close direct or inverse 
correlation between miRNAs and different proteins 
expressed in BC cells was tested. Several proteins, such as 
vascular endothelial growth factor (VEGF), EGFR, human 
epidermal growth factor receptor-2 (Her-2/neu), B-cell 
lymphoma 2 (BCL-2) and p53, are involved in breast tumour 
cell radiosensitivity and radioresistance. Given the well 
acknowledged concept that these proteins do not have the 
same expression pattern in radiosensitive and radioresistant 
BC patients, different expression of their related miRNAs 
was actually expected. Starting with the analysis of levels of 
circulating miRNAs in blood samples of patients before and 
after RT, the authors demonstrated that miR-21 and miR-206 
were up-regulated while miR-7, -34a, -29, -15 and -16 
down-regulated in radioresistant BC patients, suggesting that 
it may be possible to use circulating miRNAs to predict 
patient response to RT [54] . 
In another study, Sochor et al. evaluated the expression of 
miR-155, miR-19a, miR-181b, miR-24, relative to let-7a in 
the sera of 63 patients with early BC (EBC) and 21 healthy 
controls. These miRNAs were selected because they target 
key molecules involved in tumor growth and aggressiveness 
of BC. Analysis was conducted collecting patient serum in 
diverse phases of the disease: diagnosis, after surgery, and 
after treatment with chemotherapy and radiotherapy.  The 
data indicated that high-risk EBC patients (classified using 
current clinical prognostic factors including HER2, Ki-67 
and grade III) possessed higher serum levels of oncomiRs  
than female-healthy controls, while low-risk patients tended 
to have low expression of oncomiRs as compared to the 
high-risk ones. Finally, levels of these four BC 
pathogenesis-related oncomiRs dramatically decreased after 
combined treatment, suggesting their potential for the EBC 
patient monitoring [55]. 
The above-mentioned miR-205, known as a 
down-regulated miRNA in radioresistant BC cells, is also 
correlated with tumor recurrence and distant relapse 
(metastasis) in breast cancer. Zhang et al. performed a 
retrospective analysis on a cohort of human BC patients in 
which miRNA profiling was obtained from 207 tumor 
samples; 84% of these patients received RT. It was observed 
that patients with low miR-205 expression levels (defined as 
the bottom 20%) in their tumors had much worse distant 
relapse-free survival than those with high miR-205 [28]. The 
same trend was observed for miR-21, which seems to be a 
molecular prognostic marker for BC progression. Moreover, 
Yan et al. showed that miR-21 over-expression correlated 
with specific BC bio-pathologic features, such as advanced 
tumor stage, lymph node metastasis and poor survival of 
patients [56]. In another study, Halimi et al. investigated 
serum levels of miR-21 in BC patients after RT (25 sessions 
of radiotherapy with a total of 50 Gy irradiation) as well as in 
20 healthy volunteers. MiR-21 levels before RT were 
comparable within healthy volunteers but increased 
significantly after RT of BC patients, discriminating 
irradiated and not-irradiated patients with high specificity 
(75%) and sensitivity (80%), thus demonstrating its role as a 
biomarker of IR exposure [57] . 
Among BC subtypes, triple negative BC (TNBC) is 
characterized by a poorer survival compared to the others.  
Gasparini et al. first highlighted the correlation between 
miR-155 and the prognosis of TNBC patients: in a 
sub-cohort of 93 TNBC patients treated with RT alone or 
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with chemotherapy plus RT, miR-155 levels positively 
correlated with the overall survival of patients [21].  
Conclusions 
In recent years, many reports have demonstrated an 
important role of miRNAs in determining the response of 
cancer cells to radiations. On the light of the published data, 
miRNAs modulating DDR and/or signaling pathways tightly 
connected to cancer cell radioresistance could represent 
particularly useful targets in the contexts of novel 
experimental strategies aimed at modulating 
radioresponsivity [16]. 
Results obtained in BC cell lines have demonstrated a 
direct involvement of selected miRNAs in determining the 
radiation response, thus revealing a new mechanism by 
which tumors may be refractory to RT. MiRNAs, such as 
miR-21 [43], miR-99 [20], miR-155 [21], miR-138 [38] and many 
others, each regulating key players in different 
radiation-relevant pathways, could represent particularly 
useful weapons for the development of strategies aimed at 
modulating radioresponsivity.  
However, there is a strong need to confirm results 
obtained in BC cell lines in adequate preclinical models 
which recapitulate the disease scenario in order to draw a 
significant conclusion on the role of miRNAs in the onset of 
BC cell radioresistance as well as on their clinical utility as 
novel cancer radiosensitizers. 
Another intriguing feature of circulating miRNAs is their 
potential as novel biomarkers of radiation response: notably, 
they can predict the radioresistance of tumors before 
treatment, monitor the response through the treatment, and 
also define RT endpoints along with risks of BC recurrence 
[54,58]. However, data have been so far obtained in very small 
and heterogeneous groups of BC patients treated with 
different RT-based regimens, which obviously limits the 
current usefulness of miRNAs as predictive markers for a 
more precise stratification of patients responding to RT.  
In conclusion, research performed thus far supports a 
relevant role for miRNAs in the future of radiation oncology, 
which could hopefully provide the basis for the development 
of miRNA-based customized treatments to enhance 
radiosensitivity or to predict response of BC patients to RT. 
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